We are live on ! Find out more
GMAB icon

Genmab
GMAB

133 hedge funds and large institutions have $564M invested in Genmab in 2019 Q4 according to their latest regulatory filings, with 50 funds opening new positions, 41 increasing their positions, 27 reducing their positions, and 13 closing their positions.

New
Increased
Maintained
Reduced
Closed

285% more first-time investments, than exits

New positions opened: 50 | Existing positions closed: 13

52% more repeat investments, than reductions

Existing positions increased: 41 | Existing positions reduced: 27

37% more funds holding

Funds holding: 97 → 133 (+36)

11% more capital invested

Capital invested by funds: $511M → $564M (+$53.8M)

0% more funds holding in top 10

Funds holding in top 10: 1 → 1 (0)

2.36% less ownership

Funds ownership: 38.78% → 36.42% (-2.4%)

Holders
133
Holders Change
+36
Holders Change %
+37.11%
% of All Funds
2.62%
Holding in Top 10
1
Holding in Top 10 Change
–
Holding in Top 10 Change %
–
% of All Funds
0.02%
New
50
Increased
41
Reduced
27
Closed
13
Calls
$8K
Puts
–
Net Calls
+$8K
Net Calls Change
+$8K

Top Buyers

Rank Fund Capital Flow
1
BlackRock
BlackRock
New York
+$7.55M
2
Arrowstreet Capital
Arrowstreet Capital
Massachusetts
+$5.33M
3
Bank of America
Bank of America
North Carolina
+$4.29M
4
CS
Candriam SCA
Luxembourg
+$4.2M
5
FAM
Fred Alger Management
New York
+$4.08M

Top Sellers

Rank Fund Capital Flow
1
Citadel Advisors
Citadel Advisors
Florida
-$15.6M
2
HM
HealthCor Management
New York
-$14.1M
3
TIP
Torray Investment Partners
Maryland
-$11.8M
4
RG
Redmile Group
California
-$6.81M
5
SIG
Senator Investment Group
New York
-$6.58M
Name Holding Trade Value Shares
Change 		Change in
Stake
VFA
126
Valeo Financial Advisors
Indiana
$1K +$1.14K +52 New
MAM
127
Meeder Asset Management
Ohio
$1K +$1.24K +57 New
OPS
128
Orion Portfolio Solutions
Nebraska
$1K +$1.29K +59 New
SPIA
129
Steward Partners Investment Advisory
New York
$1K +$1.42K +65 New
FCH
130
Freestone Capital Holdings
Washington
$407 +$45.7K +2,093 +13%
HM
131
HealthCor Management
New York
– -$14.1M -696,835 Closed
SIG
132
Senator Investment Group
New York
– -$6.58M -325,000 Closed
UBS AM
133
UBS AM
Illinois
– -$4.9M -241,703 Closed
OMC
134
Old Mission Capital
Illinois
– -$4.22M -208,363 Closed
Jane Street
135
Jane Street
New York
– -$3.71M -182,955 Closed
DIM
136
DC Investments Management
Virginia
– -$669K -33,003 Closed
T. Rowe Price Associates
137
T. Rowe Price Associates
Maryland
– -$438K -21,613 Closed
OAM
138
Oxford Asset Management
United Kingdom
– -$381K -18,830 Closed
Cerity Partners
139
Cerity Partners
New York
– -$250K -12,340 Closed
BL
140
Balentine LLC
Georgia
– -$11K -529 Closed
CCA
141
Catalyst Capital Advisors
New York
– -$6K -315 Closed
TRCT
142
Tower Research Capital (TRC)
New York
– -$1K -50 Closed
AWM
143
Atticus Wealth Management
Florida
– +$196 +9 New
GWS
144
Glassman Wealth Services
Virginia
– +$262 +12 New
2 3 4 5
6

GMAB Hedge Fund Activity: Q4 2019 in Review

133 of the 5,075 institutional investors tracked by Wall St. Rank reported a position in Genmab (GMAB) for Q4 2019, worth a combined $564M — up 11% from $511M a quarter earlier.

Buyers outnumbered sellers: 50 funds opened new GMAB positions and 13 closed out — a net gain of 37 holders — while 41 added to existing stakes and 27 trimmed.

The largest buyer was BlackRock, adding an estimated $7.55M. The largest seller was Citadel Advisors, cutting an estimated $15.6M.

  • 133 institutional investors held Genmab (GMAB) as of Q4 2019, up from 97 in Q3 2019.
  • Funds reported $564M of Genmab stock for Q4 2019, up 11% quarter-over-quarter.
  • 50 funds opened new Genmab positions in Q4 2019 and 13 closed out, a net change of +37 holders.
  • The largest Genmab buyer in Q4 2019 was BlackRock, an estimated $7.55M added.
  • The largest Genmab seller in Q4 2019 was Citadel Advisors, an estimated $15.6M sold.

Based on aggregated 13F filings for Q4 2019.